Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

PHASE3CompletedINTERVENTIONAL
Enrollment

462

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Rosacea
Interventions
DRUG

Brimonidine

DRUG

placebo

Trial Locations (16)

27262

Investigator site 10, High Point

32174

Investigator site 6, Ormond Beach

33015

Investigator site 5, Miami

33027

Investigator site 8, Miramar

33175

Investigator site 7, Miami

37215

Investigator site 4, Nashville

40202

Investigator site 9, Louisville

44122

Investigator site 11, Beachwood

46032

Investigator site 3, Carmel

55432

Investigator site 14, Fridley

71913

Investigator site 2, Hot Springs

77055

Investigator site 12, Houston

77845

Investigator site 13, College Station

87106

Investigator site 1, Albuquerque

89052

Investigator site 15, Henderson

90813

Investigator site 16, Long Beach

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Watson Laboratories, Inc.

INDUSTRY

lead

Actavis Inc.

INDUSTRY

NCT02289352 - Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea | Biotech Hunter | Biotech Hunter